Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis

Drug-induced thrombotic microangiopathies present in similar fashion but have varied pathogenic mechanisms. Carfilzomib is an irreversible proteasome inhibitor. Since its initial approval as a single agent for the treatment of relapsed or refractory multiple myeloma in 2012, there have been increasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eigbire-Molen, Odianosen, Hermelin, Daniela, Blackall, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239517/
https://www.ncbi.nlm.nih.gov/pubmed/35837078
http://dx.doi.org/10.14740/jmc3932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239517/
https://www.ncbi.nlm.nih.gov/pubmed/35837078
http://dx.doi.org/10.14740/jmc3932

Ejemplares similares